Mostrar el registro sencillo del ítem
Association of active oncologic treatment and risk of death in cancer patients with COVID-19: a systematic review and meta-analysis of patient data
dc.contributor.author | Park, Robin et al. | |
dc.date.accessioned | 2021-01-12T16:27:34Z | |
dc.date.available | 2021-01-12T16:27:34Z | |
dc.date.issued | 2020-11-02 | |
dc.identifier.uri | https://doi.org/10.1080/0284186X.2020.1837946 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12663/2481 | |
dc.description.abstract | Background: Cancer patients suffer from worse coronavirus disease-2019 (COVID-19) outcomes. Whether active oncologic treatment is an additional risk factor in this population remains unclear. Therefore, here we have conducted a systematic review and meta-analysis to summarize the existing evidence for the effect of active oncologic treatment on COVID-19 outcomes. Methods: Systematic search of databases (PubMed, Embase) was conducted for studies published from inception to July 1, 2020, with a subsequent search update conducted on 10 October 2020. In addition, abstracts and presentations from major conference proceedings (ASCO, ESMO, AACR) as well as pre-print databases (medxriv, bioxriv) were searched. Retrospective and prospective studies reporting clinical outcomes in cancer patients with laboratory confirmation or clinical diagnosis of COVID-19 and details of active or recent oncologic treatment were selected. Random-effects model was applied throughout meta-analyses. Summary outcome measure was the pooled odds ratio (OR) of death for active cancer therapy versus no active cancer therapy for each of the following modalities: recent surgery, chemotherapy, targeted therapy, immunotherapy, or chemoimmunotherapy. Results: Sixteen retrospective and prospective studies (3558 patients) were included in the meta-analysis. Active chemotherapy was associated with higher risk of death compared to no active chemotherapy (OR, 1.60, 95% CI, 1.14–2.23). No significant association with risk of death was identified for active targeted therapy, immunotherapy, chemoimmunotherapy, or recent surgery. Meta-analysis of multivariate adjusted OR of death for active chemotherapy was consistently associated with higher risk of death compared to no active chemotherapy (OR, 1.42, 95% CI, 1.01–2.01). Conclusions: Active chemotherapy appears to be associated with higher risk of death in cancer patients with COVID-19. Further research is necessary to characterize the complex interactions between active cancer treatment and COVID-19. | en_US |
dc.language | English | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Infectious Diseases | en_US |
dc.subject | Coronavirus Infections | en_US |
dc.subject | Coronavirus | en_US |
dc.subject | Betacoronavirus | en_US |
dc.subject | Immunotherapy, Active | en_US |
dc.subject | Drug Therapy | en_US |
dc.subject | Molecular Targeted Therapy | en_US |
dc.title | Association of active oncologic treatment and risk of death in cancer patients with COVID-19: a systematic review and meta-analysis of patient data | en_US |
eihealth.country | Others | en_US |
eihealth.category | Infection prevention and control, including health care workers protection | en_US |
eihealth.type | Published Article | en_US |
eihealth.maincategory | Save Lives / Salvar Vidas | en_US |
dc.relation.ispartofjournal | Acta Oncologica | en_US |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |